Current Role of Standardized Uptake Value-derived Ratios in N2 Fluorine-18 Fluorodeoxyglucose Positron-emission Tomography Non-small Cell Lung Cancer

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2018 Mar 31

PMID 29600085

Citations 3

Authors

Duilio Divisi

Mirko Barone

Roberto Crisci

Affiliations

Soon will be listed here.

Abstract

Mediastinal staging is a crucial moment in management of non-small cell lung cancer (NSCLC) patients. In integrated pathways, 18-fluorine fluorodeoxyglucose positron-emission tomography (F-FDG-PET/CT) is an indispensable imaging resource with its peculiarities and its limitations. A critical review of work up protocols would certainly help to standardize procedures with important reflections also on the diagnostic value of this examination. In this regard, new semi-quantitative and semi-qualitative indexes have been proposed with the aim of increasing the accuracy of F-FDG-PET/CT in mediastinal lymph node staging. These latter, such as SUV and SUV indexes, seem to overcome the problem of spatial resolution and discrimination of malignancy by endorsing a new predictive and prognostic role.

Citing Articles

The lung cancers: staging and response, CT, F-FDG PET/CT, MRI, DWI: review and new perspectives.

Owens C, Hindocha S, Lee R, Millard T, Sharma B Br J Radiol. 2023; 96(1148):20220339.

PMID: 37097296 PMC: 10392646. DOI: 10.1259/bjr.20220339.

A Comparative Evaluation of Mediastinal Nodal SUVmax and Derived Ratios from F-FDG PET/CT Imaging to Predict Nodal Metastases in Non-Small Cell Lung Cancer.

AlRasheedi M, Han S, Thygesen H, Neilson M, Hendry F, Alkarn A Diagnostics (Basel). 2023; 13(7).

PMID: 37046427 PMC: 10093125. DOI: 10.3390/diagnostics13071209.

Is It Possible to Establish a Reliable Correlation between Maximum Standardized Uptake Value of 18-Fluorine Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography and Histological Types of Non-Small Cell Lung Cancer? Analysis of the....

Divisi D, Rinaldi M, Necozione S, Curcio C, Rea F, Zaraca F Diagnostics (Basel). 2021; 11(10).

PMID: 34679600 PMC: 8534503. DOI: 10.3390/diagnostics11101901.

References

Silvestri G, Gonzalez A, Jantz M, Margolis M, Gould M, Tanoue L . Methods for staging non-small cell lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013; 143(5 Suppl):e211S-e250S. DOI: 10.1378/chest.12-2355. View

Park H, Jeon K, Koh W, Suh G, Kim H, Kwon O . Occult nodal metastasis in patients with non-small cell lung cancer at clinical stage IA by PET/CT. Respirology. 2010; 15(8):1179-84. DOI: 10.1111/j.1440-1843.2010.01793.x. View

Kuo W, Wu Y, Wu C, Ho K, Chiu P, Wang C . Node/aorta and node/liver SUV ratios from (18)F-FDG PET/CT may improve the detection of occult mediastinal lymph node metastases in patients with non-small cell lung carcinoma. Acad Radiol. 2012; 19(6):685-92. DOI: 10.1016/j.acra.2012.02.013. View

De Leyn P, Dooms C, Kuzdzal J, Lardinois D, Passlick B, Rami-Porta R . Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small-cell lung cancer. Eur J Cardiothorac Surg. 2014; 45(5):787-98. DOI: 10.1093/ejcts/ezu028. View

Stiles B, Nasar A, Mirza F, Paul S, Lee P, Port J . Ratio of positron emission tomography uptake to tumor size in surgically resected non-small cell lung cancer. Ann Thorac Surg. 2012; 95(2):397-403. DOI: 10.1016/j.athoracsur.2012.07.038. View

Ibeas P, Cantos B, Gasent J, Rodriguez B, Provencio M . PET-CT in the staging and treatment of non-small-cell lung cancer. Clin Transl Oncol. 2011; 13(6):368-77. DOI: 10.1007/s12094-011-0670-5. View

Liu Y, Tang Y, Xue Z, Yang P, Ma K, Ma G . Ratio of lymph node to primary tumor SUVmax multiplied by maximal tumor diameter on positron emission tomography/integrated computed tomography may be a predictor of mediastinal lymph node malignancy in lung cancer. Medicine (Baltimore). 2016; 95(46):e5457. PMC: 5120955. DOI: 10.1097/MD.0000000000005457. View

Iskender I, Kadioglu S, Kosar A, Atasalihi A, Kir A . Is there any maximum standardized uptake value variation among positron emission tomography scanners for mediastinal staging in non-small cell lung cancer?. Interact Cardiovasc Thorac Surg. 2011; 12(6):965-9. DOI: 10.1510/icvts.2010.258103. View

Gomez-Caro A, Garcia S, Reguart N, Arguis P, Sanchez M, Gimferrer J . Incidence of occult mediastinal node involvement in cN0 non-small-cell lung cancer patients after negative uptake of positron emission tomography/computer tomography scan. Eur J Cardiothorac Surg. 2010; 37(5):1168-74. DOI: 10.1016/j.ejcts.2009.12.013. View

10.

Liu Y . Invalidity of SUV Measurements of Lesions in Close Proximity to Hot Sources due to "Shine-Through" Effect on FDG PET-CT Interpretation. Radiol Res Pract. 2012; 2012:867218. PMC: 3477567. DOI: 10.1155/2012/867218. View

11.

De Leyn P, Lardinois D, Van Schil P, Rami-Porta R, Passlick B, Zielinski M . ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer. Eur J Cardiothorac Surg. 2007; 32(1):1-8. DOI: 10.1016/j.ejcts.2007.01.075. View

12.

Schmidt-Hansen M, Baldwin D, Hasler E, Zamora J, Abraira V, Roque I Figuls M . PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer. Cochrane Database Syst Rev. 2014; (11):CD009519. PMC: 6472607. DOI: 10.1002/14651858.CD009519.pub2. View

13.

Cerfolio R, Bryant A . Ratio of the maximum standardized uptake value on FDG-PET of the mediastinal (N2) lymph nodes to the primary tumor may be a universal predictor of nodal malignancy in patients with nonsmall-cell lung cancer. Ann Thorac Surg. 2007; 83(5):1826-9. DOI: 10.1016/j.athoracsur.2006.12.034. View

14.

Allen T, Kendi A, Mitiek M, Maddaus M . Combined contrast-enhanced computed tomography and 18-fluoro-2-deoxy-D-glucose-positron emission tomography in the diagnosis and staging of non-small cell lung cancer. Semin Thorac Cardiovasc Surg. 2011; 23(1):43-50. DOI: 10.1053/j.semtcvs.2011.05.003. View

15.

Kaseda K, Watanabe K, Asakura K, Kazama A, Ozawa Y . Identification of false-negative and false-positive diagnoses of lymph node metastases in non-small cell lung cancer patients staged by integrated (18F-)fluorodeoxyglucose-positron emission tomography/computed tomography: A retrospective cohort study. Thorac Cancer. 2016; 7(4):473-80. PMC: 4930968. DOI: 10.1111/1759-7714.12358. View

16.

Lv Y, Yuan D, Wang K, Miao X, Qian Q, Wei S . Diagnostic performance of integrated positron emission tomography/computed tomography for mediastinal lymph node staging in non-small cell lung cancer: a bivariate systematic review and meta-analysis. J Thorac Oncol. 2011; 6(8):1350-8. DOI: 10.1097/JTO.0b013e31821d4384. View

17.

Herth F, Eberhardt R, Vilmann P, Krasnik M, Ernst A . Real-time endobronchial ultrasound guided transbronchial needle aspiration for sampling mediastinal lymph nodes. Thorax. 2006; 61(9):795-8. PMC: 2117082. DOI: 10.1136/thx.2005.047829. View

18.

Lee A, Choi S, Jung K, Park J, Lee S, Bae S . Characteristics of Metastatic Mediastinal Lymph Nodes of Non-Small Cell Lung Cancer on Preoperative F-18 FDG PET/CT. Nucl Med Mol Imaging. 2014; 48(1):41-6. PMC: 4035153. DOI: 10.1007/s13139-013-0244-2. View

19.

Al-Sarraf N, Aziz R, Gately K, Lucey J, Wilson L, McGovern E . Pattern and predictors of occult mediastinal lymph node involvement in non-small cell lung cancer patients with negative mediastinal uptake on positron emission tomography. Eur J Cardiothorac Surg. 2007; 33(1):104-9. DOI: 10.1016/j.ejcts.2007.09.026. View

20.

Paquet N, Albert A, Foidart J, Hustinx R . Within-patient variability of (18)F-FDG: standardized uptake values in normal tissues. J Nucl Med. 2004; 45(5):784-8. View